Leadership void at FDA generics office has US industry worried
This article was originally published in SRA
Executive Summary
With Greg Geba, the latest chief of the US Food and Drug Administration's Office of Generic Drugs, packing his bags on 15 March and leaving the agency after only eight months on the job, the head of the country’s generics lobbying group has voiced concern that the departure could bring disruption and distraction, resulting in the flow of information and guidance to manufacturers being blunted, with drug approvals ultimately slowed1-3.